United Therapeutics CEO Disposes $5M in Stock; Exercises Options as Company Posts Positive Clinical and Capital Actions
Martine Rothblatt, chairperson and CEO of United Therapeutics (NASDAQ: UTHR), sold about $5 million of common stock on March 24, 2026 under a pre-arranged 10b5-1 plan and exercised options to acquire 9,500 shares. The company also reported positive phase 3 TETON-2 data, published in the New England Journal of Medicine, and unveiled a $2 billion rep…